180 related articles for article (PubMed ID: 17156009)
1. alpha-Synuclein, oxidative stress and apoptosis from the perspective of a yeast model of Parkinson's disease.
Witt SN; Flower TR
FEMS Yeast Res; 2006 Dec; 6(8):1107-16. PubMed ID: 17156009
[TBL] [Abstract][Full Text] [Related]
2. Heat shock prevents alpha-synuclein-induced apoptosis in a yeast model of Parkinson's disease.
Flower TR; Chesnokova LS; Froelich CA; Dixon C; Witt SN
J Mol Biol; 2005 Sep; 351(5):1081-100. PubMed ID: 16051265
[TBL] [Abstract][Full Text] [Related]
3. Yeast unfolds the road map toward alpha-synuclein-induced cell death.
Franssens V; Boelen E; Anandhakumar J; Vanhelmont T; Büttner S; Winderickx J
Cell Death Differ; 2010 May; 17(5):746-53. PubMed ID: 20019751
[TBL] [Abstract][Full Text] [Related]
4. Rescuing defective vesicular trafficking protects against alpha-synuclein toxicity in cellular and animal models of Parkinson's disease.
Lashuel HA; Hirling H
ACS Chem Biol; 2006 Aug; 1(7):420-4. PubMed ID: 17168518
[TBL] [Abstract][Full Text] [Related]
5. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.
Chu Y; Dodiya H; Aebischer P; Olanow CW; Kordower JH
Neurobiol Dis; 2009 Sep; 35(3):385-98. PubMed ID: 19505575
[TBL] [Abstract][Full Text] [Related]
6. Antiapoptotic property of human alpha-synuclein in neuronal cell lines is associated with the inhibition of caspase-3 but not caspase-9 activity.
Li W; Lee MK
J Neurochem; 2005 Jun; 93(6):1542-50. PubMed ID: 15935070
[TBL] [Abstract][Full Text] [Related]
7. Rescue of alpha-synuclein cytotoxicity by insulin-like growth factors.
Kao SY
Biochem Biophys Res Commun; 2009 Jul; 385(3):434-8. PubMed ID: 19470380
[TBL] [Abstract][Full Text] [Related]
8. A Saccharomyces cerevisiae strain unable to store neutral lipids is tolerant to oxidative stress induced by α-synuclein.
Sere YY; Regnacq M; Colas J; Berges T
Free Radic Biol Med; 2010 Dec; 49(11):1755-64. PubMed ID: 20850523
[TBL] [Abstract][Full Text] [Related]
9. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants.
Koo HJ; Choi MY; Im H
Biochem Biophys Res Commun; 2009 Aug; 386(1):165-9. PubMed ID: 19501571
[TBL] [Abstract][Full Text] [Related]
10. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
[TBL] [Abstract][Full Text] [Related]
11. Toxic effects of dopamine metabolism in Parkinson's disease.
Hattoria N; Wanga M; Taka H; Fujimura T; Yoritaka A; Kubo S; Mochizuki H
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S35-8. PubMed ID: 19131041
[TBL] [Abstract][Full Text] [Related]
12. Alpha-synuclein overexpression and aggregation exacerbates impairment of mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells.
Parihar MS; Parihar A; Fujita M; Hashimoto M; Ghafourifar P
Int J Biochem Cell Biol; 2009 Oct; 41(10):2015-24. PubMed ID: 19460457
[TBL] [Abstract][Full Text] [Related]
13. A pragmatic approach to biochemical systems theory applied to an alpha-synuclein-based model of Parkinson's disease.
Sass MB; Lorenz AN; Green RL; Coleman RA
J Neurosci Methods; 2009 Apr; 178(2):366-77. PubMed ID: 19136028
[TBL] [Abstract][Full Text] [Related]
14. Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease?
Maguire-Zeiss KA; Short DW; Federoff HJ
Brain Res Mol Brain Res; 2005 Mar; 134(1):18-23. PubMed ID: 15790526
[TBL] [Abstract][Full Text] [Related]
15. Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson's disease.
Angot E; Brundin P
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S143-7. PubMed ID: 20082977
[TBL] [Abstract][Full Text] [Related]
16. Disruption of dopamine homeostasis underlies selective neurodegeneration mediated by alpha-synuclein.
Park SS; Schulz EM; Lee D
Eur J Neurosci; 2007 Dec; 26(11):3104-12. PubMed ID: 18005066
[TBL] [Abstract][Full Text] [Related]
17. Controlling the mass action of alpha-synuclein in Parkinson's disease.
Kim C; Lee SJ
J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease.
Azeredo da Silveira S; Schneider BL; Cifuentes-Diaz C; Sage D; Abbas-Terki T; Iwatsubo T; Unser M; Aebischer P
Hum Mol Genet; 2009 Mar; 18(5):872-87. PubMed ID: 19074459
[TBL] [Abstract][Full Text] [Related]
19. Alpha-synuclein and Parkinson's disease: a proteomic view.
Fasano M; Lopiano L
Expert Rev Proteomics; 2008 Apr; 5(2):239-48. PubMed ID: 18466054
[TBL] [Abstract][Full Text] [Related]
20. Dopamine and the dopamine oxidation product 5,6-dihydroxylindole promote distinct on-pathway and off-pathway aggregation of alpha-synuclein in a pH-dependent manner.
Pham CL; Leong SL; Ali FE; Kenche VB; Hill AF; Gras SL; Barnham KJ; Cappai R
J Mol Biol; 2009 Apr; 387(3):771-85. PubMed ID: 19361420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
